Toggle Health Problems and D

Ivermectin reduced COVID-19 deaths in Peru by 14X, after new president halted it, the death rate increased 13X – March 18, 2021

Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=.002 for effect by state, then 13-fold increase after ivermectin use restricted

 Download the Preprint from VitaminDWiki
Juan J. Chamie-Quintero,a Jennifer A. Hibberd,b David E Scheimc


Note: The sections of Peru of getting the most Ivermectin had the biggest declines in excess deaths

VitaminDWiki pages with IVERMECTIN in title (8 as of Jan 2022)

This list is automatically updated

Items found: 8

COVID-19 treated by Vitamin D - studies, reports, videos

As of April 29, 2022, the VitaminDWiki COVID page had:  19 trial results,   37 meta-analyses and reviews,   Mortality studies   see related:   Governments,   HealthProblems,   Hospitals,  Dark Skins,   26 risk factors are ALL associated with low Vit D,   Fight COVID-19 with 50K Vit D weekly   Vaccines   Take lots of Vitamin D at first signs of COVID   126 COVID Clinical Trials using Vitamin D (March 2023)   Cost to prevent a COVID death: 11 dollars of Vitamin D - Nov 2022
5 most-recently changed Virus entries

  • Image
    • The above image is automatically updated

Introduction. On May 8, 2020, Peru’s Ministry of Health approved ivermectin (IVM), a drug of Nobel Prize-honored distinction, for inpatient and outpatient treatment of COVID-19. As IVM treatments proceeded in that nation of 33 million residents, excess deaths decreased 14-fold over four months through December 1, 2020, consistent with clinical benefits of IVM for COVID-19 as have emerged in several RCTs. But after IVM use was sharply restricted under a new president, excess deaths then increased 13fold.

Methods. To evaluate possible IVM treatment effects suggested by these aggregate trends, excess deaths were analyzed by state for ages > 60 in Peru’s 25 states. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations and seropositivity rates were also examined.

Results. The 25 states of Peru were grouped by extent of IVM distributions: maximal (mass IVM distributions through operation MOT, a broadside effort led by the army); medium (locally managed IVM distributions); and minimal (restrictive policies in one state, Lima).
The mean reduction in excess deaths 30 days after peak deaths was

  • 74% for the maximal IVM distribution group,
  • 53% for the medium group and
  • 25% for Lima. (minimal)

Reduction of excess deaths is correlated with extent of IVM distribution by state with p<0.002 using the Kendall Tb test.

Conclusion. Mass treatments with IVM, a drug safely used in 3.7 billion doses worldwide since 1987, most likely caused the 14-fold reductions in excess deaths in Peru, prior to their 13-fold increase after IVM policy was reversed. This strongly suggests that IVM treatments can likewise effectively complement immunizations to help eradicate COVID-19. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Created by admin. Last Modification: Thursday January 6, 2022 02:23:15 GMT-0000 by admin. (Version 8)